Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ibrahim Aldoss

Showing results (91-100 of 233) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|August 1, 2023
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewFranco Locatelli, Bijal Shah, Tracy Thomas, et al.
British Journal of Haematology|June 10, 2025
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remissionJose Tinajero, Dat Ngo, Maria Motta, et al.
Blood Cancer Journal|July 12, 2023
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemiaIbrahim Aldoss, Samer K Khaled, Yan Wang, et al.
Cancer|May 2, 2021
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemiaGautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 25, 2017
Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor RescueAmandeep Salhotra, Yuan Shan, Ni-Chun Tsai, et al.
American Journal of Hematology|November 23, 2020
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemiaShukaib Arslan, Jianying Zhang, Prajwal Dhakal, et al.
Cancer Research|February 5, 2024
Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory DevelopmentLior Goldberg, Eric R Haas, Ryan Urak, et al.
Bone Marrow Transplantation|April 20, 2022
Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host diseaseAmandeep Salhotra, Min Talley, Xiwei Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemiaDan Douer, Ibrahim Aldoss, Matthew A Lunning, et al.
Haematologica|March 20, 2025
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panelEmily Curran, Marlise R Luskin, Houda Alachkar, et al.
Pageof 24

Showing results (91-100 of 233) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|August 1, 2023
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewFranco Locatelli, Bijal Shah, Tracy Thomas, et al.
British Journal of Haematology|June 10, 2025
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remissionJose Tinajero, Dat Ngo, Maria Motta, et al.
Blood Cancer Journal|July 12, 2023
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemiaIbrahim Aldoss, Samer K Khaled, Yan Wang, et al.
Cancer|May 2, 2021
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemiaGautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 25, 2017
Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor RescueAmandeep Salhotra, Yuan Shan, Ni-Chun Tsai, et al.
American Journal of Hematology|November 23, 2020
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemiaShukaib Arslan, Jianying Zhang, Prajwal Dhakal, et al.
Cancer Research|February 5, 2024
Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory DevelopmentLior Goldberg, Eric R Haas, Ryan Urak, et al.
Bone Marrow Transplantation|April 20, 2022
Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host diseaseAmandeep Salhotra, Min Talley, Xiwei Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemiaDan Douer, Ibrahim Aldoss, Matthew A Lunning, et al.
Haematologica|March 20, 2025
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panelEmily Curran, Marlise R Luskin, Houda Alachkar, et al.
Pageof 24